ABBV-368
Sponsors
AbbVie
Conditions
Advanced Solid TumorsAdvanced Solid Tumors CancerCancerHead and Neck CancerMetastatic Solid TumorsNon-small-cell-lung-cancer (NSCLC)Triple-Negative Breast Cancer (TNBC)
Phase 1
A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors
CompletedNCT03071757
Start: 2017-03-21End: 2022-04-13Updated: 2022-04-28
A Study to Assess the Effects of Multiple Study Drug Regimens in Subjects With Newly Diagnosed Locally Advanced Head and Neck Squamous Cell Carcinoma
TerminatedNCT03818542
Start: 2020-01-22End: 2020-09-23Updated: 2020-12-31
A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors
Active, not recruitingNCT03893955
Start: 2019-05-21End: 2026-03-31Target: 150Updated: 2025-08-12
A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-368 Plus Tilsotolimod and Other Therapy Combinations in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
CompletedNCT04196283
Start: 2020-01-22End: 2022-10-27Updated: 2023-02-27